Ecnoglutide is cAMP-biased GLP-1 receptor agonist (Sciwind Biosciences; XW003). Ecnoglutide is a once-weekly GLP-1 injection developed by Sciwind Biosciences. It was approved in China in 2026 but is not approved in the US. A pill version is in development.
Education only. Not medical advice. No dosing information.
Status (verified Oct 29, 2026): Approved in China (T2D Jan 2026; weight management Mar 2026); not FDA approved. Source: Approved in China for long-term weight management
Evidence tier: Phase 3 trials; approved outside US
Get alerts on legal status changes ->
What it is
Ecnoglutide is a once-weekly GLP-1 injection developed by Sciwind Biosciences. It was approved in China in 2026 but is not approved in the US. A pill version is in development.
How it works
A GLP-1 analog designed to favor one signaling route (cAMP) inside cells, an approach aimed at strong effects with better tolerability.
What it's researched for
Type 2 diabetes, weight management, and obesity with sleep apnea or knee osteoarthritis.
Where it shows up on Peptide Horizon
Regulatory and research timeline
- 2025-09: Phase 3 obesity trial published (Lancet Diabetes Endocrinol) (source)
- 2025-10: Phase 3 vs dulaglutide published (source)
- 2026-01: First approval in China (type 2 diabetes) (source)
- 2026-03: Approved in China for long-term weight management (source)
Key trials and studies
- Phase 3 obesity (Lancet Diabetes Endocrinol 2025; NCT05813795)
- Phase 3 vs dulaglutide in T2D (Lancet Diabetes Endocrinol 2025)
- Ecnoglutide: First Approvals (Drugs 2026)
- Phase 3 sleep apnea (NCT07387094)
FAQ
Is ecnoglutide FDA approved?
No. It was approved in China in 2026 but has no FDA approval.
What is a 'biased' GLP-1?
It preferentially triggers one signaling pathway (cAMP) after binding the GLP-1 receptor.
Is there an ecnoglutide pill?
An oral version is in clinical trials.
Related peptides
- dulaglutide FDA status and research
- semaglutide FDA status and research
- aleniglipron FDA status and research
Get alerts on legal status changes
Free email alerts when the FDA, HHS or another regulator changes the status of Ecnoglutide or other peptides. Get alerts ->
Sources
- https://pubmed.ncbi.nlm.nih.gov/40555243
- https://pubmed.ncbi.nlm.nih.gov/40854315
- https://pubmed.ncbi.nlm.nih.gov/42412371
- https://clinicaltrials.gov/study/NCT07387094
Editorial review - Last reviewed Oct 29, 2026